Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Equinox Investigators.
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
J Thromb Haemost. 2011; 9(1):92-99
Doi: 10.1111/j.1538-7836.2010.04100.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Pilger Ernst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Idraparinux, a long acting inhibitor of factor (F) Xa, is as effective as standard anticoagulant therapy for patients with symptomatic deep venous thrombosis. We investigated the potential use of the biotinylated molecule, idrabiotaparinux. Biotinylation enables reversal of the anticoagulant effect. Methods: We performed a randomized double-blind trial in 757 patients with symptomatic deep venous thrombosis, comparing equimolar doses of idrabiotaparinux (3 mg) with idraparinux (2.5 mg), both given subcutaneously, once weekly for 6 months. Inhibition of FXa activity was measured at days 15, 36, 57, 92 and 183. The efficacy outcome was recurrent venous thromboembolism. The safety outcomes were clinically relevant bleeding and death. Results: Inhibition of FXa was similar in the two treatment groups at each time point of measurement. Recurrent venous thromboembolism during the 6-month treatment period occurred in nine of 386 patients (2.3%) in the idrabiotaparinux group and in 12 of 371 patients (3.2%) in the idraparinux group, a difference of - 0.9% (95% confidence interval, -3.2-1.4%). The incidence of clinically relevant bleeding was 5.2% in the idrabiotaparinux group and 7.3% in the idraparinux group (P = 0.29), a difference of - 2.1% (95% confidence interval, -5.6-1.4%). Six patients (1.6%) who received idrabiotaparinux died, compared with 12 patients (3.2%) given idraparinux, a difference of - 1.7% (95% confidence interval, -3.9-0.5%). Conclusions: Idrabiotaparinux has a similar time course of FXa inhibition, efficacy and safety to idraparinux for the treatment of deep venous thrombosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Anticoagulants - administration & dosage Anticoagulants - adverse effects
- Biotin - administration & dosage Biotin - adverse effects Biotin - analogs & derivatives
- Blood Coagulation - drug effects
- Double-Blind Method -
- Drug Administration Schedule -
- Drug Administration Schedule -
- Factor Xa - antagonists & inhibitors
- Female -
- Hemorrhage - chemically induced
- Humans -
- Injections, Subcutaneous -
- Male -
- Middle Aged -
- Oligosaccharides - administration & dosage Oligosaccharides - adverse effects
- Recurrence -
- Risk Assessment -
- Time Factors -
- Treatment Outcome -
- Treatment Outcome -
- Venous Thrombosis - blood Venous Thrombosis - drug therapy Venous Thrombosis - mortality
- Find related publications in this database (Keywords)
- auticoagulants
- bioequipotency
- deep venous thrombosis
- treatment randomized trial